Safety and Tolerability Assessment of TEV-53408 in Adult Patients with Celiac Disease: A Phase 1b Clinical Trial

The primary objective of this Phase 1b study is to characterize the **safety** and **tolerability** of TEV-53408 in adults diagnosed with **Celiac disease**. Understanding the safety profile and tolerability of TEV-53408 is clinically relevant as it may inform future therapeutic strategies for managing Celiac disease, a condition characterized by an immune response to ingested gluten, leading to intestinal damage and various systemic symptoms.

The clinical trial involves a total of **14 participants** diagnosed with **celiac disease**. The study population includes both male and female subjects, with an age range spanning from **18 to 64 years**. Participants were selected without targeting any vulnerable populations. The general health status of the participants is not specified, and there are no specific lifestyle considerations such as diet or physical activity mentioned. The selection criteria for the trial population have not been detailed by the sponsor.

The clinical trial is designed to evaluate the safety and tolerability of **TEV-53408** in adults diagnosed with **celiac disease**. This study is structured as a Phase 1b trial, employing a randomized, double-blind, and controlled methodology to ensure the reliability and validity of the results. The trial is anticipated to commence recruitment on December 1, 2023, and is projected to conclude by December 31, 2025, providing a comprehensive assessment over a two-year period.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, where eligibility criteria will be assessed. This initial visit is crucial for confirming the diagnosis of **celiac disease** and ensuring that participants meet all necessary inclusion criteria while not falling under any exclusion criteria. Following successful screening, participants will be randomly assigned to either the treatment or control group, maintaining the double-blind nature of the study.

Throughout the trial, participants will attend regular follow-up visits, which are essential for monitoring the safety and tolerability of the investigational product. These visits will include assessments such as physical examinations, laboratory tests, and questionnaires to evaluate any adverse events or changes in health status. The frequency and specific procedures of these follow-up visits will be determined by the study protocol to ensure consistent data collection and participant safety.

The end-of-study visit marks the final assessment point, where comprehensive evaluations will be conducted to gather data on the long-term effects and overall safety profile of **TEV-53408**. The expected length of participant involvement will span the entire duration of the trial, from the initial screening to the end-of-study visit, unless early termination is warranted. Conditions that may lead to early withdrawal from the study include significant adverse events, non-compliance with study procedures, or withdrawal of consent by the participant.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided data. As such, no further details can be included in this description.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 3 study, indicating it is in the advanced stages of clinical research. The estimated recruitment start date is December 1, 2023, with an anticipated end date of December 31, 2025. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, Phase 3 trials typically focus on confirming the effectiveness of a treatment, monitoring side effects, and collecting information that will allow the treatment to be used safely. The trial will likely involve systematic data collection and analysis to evaluate the treatment's impact on the disease, using scientifically validated methods and tools appropriate for the condition under investigation. The trial's design will ensure that efficacy assessments are conducted at predetermined intervals to provide comprehensive data on the treatment's performance over time.